Cerus Corporation (FRA:CU2)
Germany · Delayed Price · Currency is EUR | Market Cap | 443.03M +106.9% |
| Revenue (ttm) | 187.82M +17.0% |
| Net Income | -8.28M |
| EPS | -0.04 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 2.220 |
| Previous Close | 2.200 |
| Day's Range | 2.220 - 2.260 |
| 52-Week Range | 0.990 - 2.600 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 3, 2026 |
About Cerus
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma do... [Read more]
Financial Performance
In 2025, Cerus's revenue was $206.13 million, an increase of 14.35% compared to the previous year's $180.27 million. Losses were -$15.63 million, -25.29% less than in 2024.
Financial numbers in USD Financial StatementsNews
Cerus closes debt facility up to $110M
Cerus (CERS) Corporation announced the closing of a new debt facility with MidCap Financial, providing up to $110M. The facility consists of a 5-year term loan and an asset-backed revolving…
Cerus Corporation Closes New Debt Facility of Up to $110 Million
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today the closing of a new debt facility with MidCap Financial (MidCap), providing up to $110 million. The facility consist...
Cerus Transcript: AGM 2026
The meeting confirmed a quorum, introduced leadership changes, and presented four proposals, all of which were approved by shareholders. No questions were submitted, and voting results will be reported on Form 8-K within four business days.
Bradley L. Radoff Announces Intent to Withhold Votes from Chair and CEO William Greenman and Director Ann Lucena
HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff, a significant shareholder of Cerus Corporation (NASDAQ: CERS) (“Cerus” or the “Company”), today announced his intention to withhold support for the Company...
Cerus management to meet with Craig-Hallum
Meeting to be held in Chicago and Milwaukee on May 14 hosted by Craig-Hallum.
Cerus upgraded to Buy from Neutral at BTIG
BTIG upgraded Cerus (CERS) to Buy from Neutral with a $4 price target
Cerus Earnings Call Transcript: Q1 2026
Q1 2026 saw 24% product revenue growth, driven by strong platelet and IFC demand, with raised full-year guidance and continued margin discipline. Innovation and new contracts in the U.S. and EMEA support long-term growth, despite inflation and regulatory uncertainties.
Cerus Earnings release: Q1 2026
Cerus released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
Cerus Quarterly report: Q1 2026
Cerus has published its Q1 2026 quarterly earnings report on April 30, 2026.
Cerus reports Q1 EPS (1c), consensus (4c)
Reports Q1 revenue $59.9M, consensus $51.18M. “We delivered a strong start to 2026, with first quarter performance driven by strength across our business, in particular by increasing demand for our…
Cerus raises FY26 product revenue view to $227M-$231M from $224M-$228M
Consensus $233.9M.
Cerus Corporation Announces First Quarter 2026 Financial Results
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for the first quarter ended March 31, 2026, and provided a business update. “We delivered a strong ...
Cerus announces new, four-year supply agreement with EFS
Cerus (CERS) Corporation announced the signing of a new, four-year supply agreement with Etablissement Francais du Sang, EFS, the French Blood Establishment, for the INTERCEPT Blood System. The agreem...
Cerus Corporation Announces New, Four-Year Supply Agreement with French Blood Establishment for INTERCEPT Blood System
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today the signing of a new, four-year supply agreement with Établissement Français du Sang (EFS), the French Blood Establis...
Cerus Proxy statement: Proxy filing
Cerus filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
Cerus Proxy statement: Proxy filing
Cerus filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
Cerus Slides: Corporate presentation
Cerus has posted slides in relation to its latest quarterly earnings report, which was published on April 22, 2026.
Cerus Corporation to Release First Quarter 2026 Financial Results on April 30, 2026
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2026 financial results will be released on Thursday, April 30, 2026, after the close of the st...
Cerus names Vivek Jayaraman as CEO
Cerus (CERS) “announced that Vivek Jayaraman, Cerus’ chief operating officer, will be promoted to president and chief executive officer, effective July 1, 2026. William “Obi” Greenman will become exec...
Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that Vivek Jayaraman, Cerus' chief operating officer, will be promoted to president and chief executive officer, effe...
Cerus Slides: Corporate presentation
Cerus has posted slides in relation to its latest quarterly earnings report, which was published on March 6, 2026.
Cathie Wood’s ARK Investment buys 612K shares of Cerus today
20:54 EST Cathie Wood’s ARK Investment buys 612K shares of Cerus (CERS) today
Cerus Transcript: TD Cowen 46th Annual Health Care Conference
INTERCEPT Blood System continues to expand its global leadership in transfusion safety, leveraging strong U.S. and international growth, a robust product pipeline, and strategic partnerships like the BCA agreement. Double-digit revenue growth is expected through 2026, with new product launches and geographic expansion driving future gains.
Cerus Earnings Call Transcript: Q4 2025
Record 2025 revenue and product growth were driven by strong U.S. and EMEA performance, successful INT200 launch, and expanding IFC adoption. 2026 guidance projects continued revenue and EBITDA growth, with BCA agreement and international expansion as key drivers.
Cerus Annual report: Q4 2025
Cerus has published its Q4 2025 annual report on March 2, 2026.